Corvus Pharmaceuticals, Inc.
CRVS
$15.97
$0.161.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -190.12% | -1.72% | 74.74% | -87.66% | 366.50% |
| Total Depreciation and Amortization | 31.82% | 30.00% | 33.33% | 38.10% | -4.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.68% | -60.29% | -96.70% | -0.86% | -7,924.50% |
| Change in Net Operating Assets | -62.50% | 174.30% | -498.55% | 630.83% | -30.59% |
| Cash from Operations | -25.55% | -8.58% | -51.34% | -5.40% | -60.23% |
| Capital Expenditure | -152.78% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,482.92% | 279.12% | 32.70% | -15.33% | 61,228.57% |
| Cash from Investing | -3,513.76% | 278.86% | 32.70% | -15.98% | 60,714.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 68,267.74% | -99.89% | 620.00% | 118.04% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 68,267.74% | -99.89% | 620.00% | 17.78% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,049.64% | -57.91% | -16.37% | 31.24% | 27.56% |